Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal

Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group, have now been published in a peer review journal FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate The publication in ‘npj Vaccines’ […]

Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission

Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. […]

Open Orphan #ORPH – Result of General Meeting

Open Orphan is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Company’s proposed merger with hVIVO plc and the Proposed Placing, all of the Resolutions put to the meeting were duly passed. The Board is excited by the growth potential of the Enlarged Group following completion of […]